Offering fragile X syndrome carrier screening: A prospective mixed-methods observational study comparing carrier screening of pregnant and non-pregnant women in the general population

BMJ Open

Volumn 3, Issue 9, 2013, Pages

  Martyn, M ^a   Anderson, V ^a,b,c   Archibald, A ^a,c,d   Carter, R ^e   Cohen, J ^f   Delatycki, M ^a,g   Donath, S ^a,c   Emery, J ^h   Halliday, J ^a,c   Hill, M ^a,i   Sheffield, L ^a,d,j   Slater, H ^a,c,d   Tassone, F ^k,l   Younie, S ^e   Metcalfe, S ^a,c  

^a MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d VICTORIAN CLINICAL GENETICS SERVICES   (Australia)

^e DEAKIN UNIVERSITY   (Australia)

^f MONASH UNIVERSITY   (Australia)

^g AUSTIN HEALTH   (Australia)

^h UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

ⁱ GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^j GenesFX Health Pty Ltd   (Australia)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; FRAGILE X SYNDROME; GENETIC SCREENING; HEALTH ECONOMICS; HUMAN; INTERMETHOD COMPARISON; INTERVIEW; MAJOR CLINICAL STUDY; MULTIMETHOD STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COUNSELING; PATIENT DECISION MAKING; POPULATION; PREGNANT WOMAN; PROSPECTIVE STUDY; QUESTIONNAIRE; SOCIAL PSYCHOLOGY;

EID: 84885342020     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003660     Document Type: Article

References (71)

1. Godard B, Leo ten K, Evers-Kiebooms G, et al Population genetic screening programmes: principles, techniques, practices, and policies. Eur J Hum Genet 2003;11:S49-87. (Pubitemid 38263569)
2. Teutsch SM, Bradley LA, Palomaki G.E., et al The evaluation of genomic applications in practice and prevention (EGAPP) initiative: methods of the EGAPP working group. Genet Med 2009;11:3-14.
3. Hill MK, Archibald AD, Cohen J, bmjopen-2013-003660.R1. A systematic review of population screening for fragile X syndrome. Genet Med 2010;12:396-410.
4. Finucane B, Abrams L, Cronister A., et al Genetic counseling and testing for FMR1 gene mutations: practice guidelines of the national society of genetic counselors. J Genet Couns 2012;21:752-60.
5. Pieretti M, Zhang FP, Fu Y.H., et al Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 1991;66:817-22. (Pubitemid 121001715)
6. Verkerk AJ, Pieretti M, Sutcliffe J.S., et al Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991;65:905-14. (Pubitemid 121001321)
7. Bell MV, Hirst MC, Nakahori Y, et al Physical mapping across the fragile X: hypermethylation and clinical expression of the fragile X syndrome. Cell 1991;64:861-6. (Pubitemid 121001172)
8. Fu YH, Kuhl DP, Pizzuti A, et al Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 1991;67:1047-58. (Pubitemid 121001519)
9. Yu S, Mulley J, Loesch D., et al Fragile-X syndrome: unique genetics of the heritable unstable element. Am J Hum Genet 1992;50:968-80.
10. HGSA. Best practice fragile X testing and analysis guidelines for Australasian laboratories, 2012.
11. Kronquist KE, Sherman SL, Spector EB Clinical significance of tri-nucleotide repeats in Fragile X testing: a clarification of American College of Medical Genetics guidelines. Genet Med 2008;10:845-7.
12. Berkenstadt M, Ries-Levavi L, Cuckle H., et al Preconceptional and prenatal screening for fragile X syndrome: experience with 40,000 tests. Prenat Diagn 2007;27:991-4. (Pubitemid 350114294)
13. Nolin SL, Lewis FA III, Ye LL, et al Familial transmission of the FMR1 CGG repeat. Am J Hum Genet 1996;59:1252-61. (Pubitemid 26394116)
14. Cornish K, Turk J, Hagerman R. The fragile X continuum: new advances and perspectives. J Intellect Disabil Res 2008;52(Pt 6):469-82. (Pubitemid 351712317)
15. Hagerman R, Hagerman P. Fragile X syndrome: diagnosis, treatment, and research. Baltimore: Johns Hopkins University Press, 2002.
16. Davids JR, Hagerman RJ, Eilert RE Orthopaedic aspects of fragile-X syndrome. J Bone Joint Surg Am 1990;72:889-96. (Pubitemid 20246894)
17. Hagerman RJ, Altshul-Stark D, McBogg P. Recurrent otitis media in the fragile X syndrome. Am J Dis Child 1987;141:184-7. (Pubitemid 17002554)
18. Hatton DD, Buckley E, Lachiewicz A., et al Ocular status of boys with fragile X syndrome: a prospective study. J AAPOS 1998;2:298-302. (Pubitemid 128676831)
19. Wirojanan J, Jacquemont S, Diaz R., et al The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med 2009;5:145-50.
20. Hagerman RJ, Berry-Kravis E, Kaufmann W.E., et al Advances in the treatment of fragile X syndrome. Pediatrics 2009;123:378-90.
21. Rueda JR, Ballesteros J, Tejada MI Systematic review of pharmacological treatments in fragile X syndrome. BMC Neurol 2009;9:53.
22. Berry-Kravis E.M., Hessl D, Rathmell B., et al Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med 2012;4:152ra27.
23. Jacquemont S, Curie A, Des Portes V, et al Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med 2011;3:64ra1.
24. Paribello C, Tao L, Folino A., et al Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol 2010;10:91.
25. Kesler SR, Lightbody AA, Reiss AL Cholinergic dysfunction in fragile X syndrome and potential intervention: a preliminary 1H MRS study. Am J Med Genet 2009;149A:403-7.
26. Schwartz CE, Dean J, Howard-Peebles PN, et al Obstetrical and gynecological complications in fragile X carriers: a multicenter study. Am J Med Genet 1994;51:400-2. (Pubitemid 24197711)
27. Allingham-Hawkins D.J., Babul-Hirji R, Chitayat D., et al Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study-preliminary data. Am J Med Genet 1999;83:322-5. (Pubitemid 29162637)
28. Sherman SL. Premature ovarian failure in the fragile X syndrome. Am J Med Genet 2000;97:189-94. (Pubitemid 32059206)
29. Rodriguez-Revenga L., Madrigal I, Pagonabarraga J., et al Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families. Eur J Hum Genet 2009;17:1359-62.
30. Hagerman RJ, Leehey M, Heinrichs W., et al Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 2001;57:127-30. (Pubitemid 32634862)
31. Jacquemont S, Hagerman RJ, Leehey M, et al Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet 2003;72:869-78. (Pubitemid 36403306)
32. Coffee B, Keith K, Albizua I., et al Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am J Hum Genet 2009;85:503-14.
33. Fernandez-Carvajal I., Walichiewicz P, Xiaosen X., et al Screening for expanded alleles of the FMR1 gene in blood spots from newborn males in a Spanish population. J Mol Diagn 2009;11:324-9.
34. Levesque S, Dombrowski C, Morel M.L., et al Screening and instability of FMR1 alleles in a prospective sample of 24,449 mother-newborn pairs from the general population. Clin Genet 2009;76:511-23.
35. Hantash FM, Goos DM, Crossley B, et al FMR1 premutation carrier frequency in patients undergoing routine population-based carrier screening: insights into the prevalence of fragile X syndrome, fragile X-associated tremor/ataxia syndrome, and fragile X-associated primary ovarian insufficiency in the United States. Genet Med 2011;13:39-45.
36. Tassone F, Iong KP, Tong T.H., et al FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. Genome Med 2012;4:100.
37. Spence WC, Black SH, Fallon L, et al Molecular fragile X screening in normal populations. Am J Med Genet 1996;64:181-3.
38. Pesso R, Berkenstadt M, Cuckle H., et al Screening for fragile X syndrome in women of reproductive age. Prenat Diagn 2000;20:611-14. (Pubitemid 30598904)
39. Ryynanen M, Heinonen S, Makkonen M., et al Feasibility and acceptance of screening for fragile X mutations in low-risk pregnancies. Eur J Hum Genet 1999;7:212-16. (Pubitemid 29150232)
40. Toledano-Alhadef H., Basel-Vanagaite L, Magal N., et al Fragile-X carrier screening and the prevalence of premutation and full-mutation carriers in Israel. Am J Hum Genet 2001;69:351-60. (Pubitemid 32695207)
41. Cronister A, DiMaio M, Mahoney M.J., et al Fragile X syndrome carrier screening in the prenatal genetic counseling setting. Genet Med 2005;7:246-50. (Pubitemid 40638070)
42. Anido A, Carlson LM, Taft L, et al Women's attitudes toward testing for fragile X carrier status: a qualitative analysis. J Genet Couns 2005;14:295-306. (Pubitemid 41095423)
43. Metcalfe S, Jacques A, Archibald A., et al A model for offering carrier screening for fragile X syndrome to nonpregnant women: results from a pilot study. Genet Med 2008;10:525-35.
44. Geva E, Yaron Y, Shomrat R., et al The risk of fragile X premutation expansion is lower in carriers detected by general prenatal screening than in carriers from known fragile X families. Genet Test 2000;4:289-92.
45. Fanos JH, Spangner KA, Musci TJ Attitudes toward prenatal screening and testing for Fragile X. Genet Med 2006;8:129-33.
46. Musci TJ, Caughey AB Cost-effectiveness analysis of prenatal population-based fragile X carrier screening. Am J Obstet Gynecol 2005;192:1905-12.
47. Archibald AD, Jaques AM, et al It's something I need to consider: decisions about carrier screening for fragile X syndrome in a population of non-pregnant women. Am J Med Genet A 2009;149A:2731-8.
48. Bekker H, Thornton JG, Airey C.M., et al Informed decision making: an annotated bibliography and systematic review. Health Technol Assess 1999;3:1-156.
49. Marteau TM, Dormandy E, Michie S. A measure of informed choice. Health Expect 2001;4:99-108. (Pubitemid 32464021)
50. Jaques AM, Halliday JL, Bell RJ Do women know that prenatal testing detects fetuses with Down syndrome? J Obstet Gynaecol 2004;24:647-51. (Pubitemid 39655422)
51. Jaques AM, Sheffield LJ, Halliday JL Informed choice in women attending private clinics to undergo first-trimester screening for Down syndrome. Prenat Diagn 2005;25:656-64. (Pubitemid 41176400)
52. Rowe HJ, Fisher JR, Quinlivan JA Are pregnant Australian women well informed about prenatal genetic screening? A systematic investigation using the Multidimensional Measure of Informed Choice. Aust N Z J Obstet Gynaecol 2006;46:433-9. (Pubitemid 44309084)
53. Van den Berg M, Timmermans DR, Ten Kate LP, et al. Informed decision-making in the context of prenatal screening. Patient Educ Couns 2006;63:110-17. (Pubitemid 44331541)
54. Archibald AD, Hickerton CL, Jaques A.M., et al It's about having the choice: stakeholder perceptions of population-based genetic carrier screening for fragile X syndrome. Am J Med Genet A 2013;161A:48-58.
55. Ames AG, Jaques A, Ukoumunne O.C., et al Development of a fragile X syndrome (FXS) knowledge scale: towards a modified multidimensional measure of informed choice for FXS population carrier screening. Health Expect Published Online First: 2012/10/17. doi:10.1111/hex.12009
56. Britt H, Miller G. ed General practice in Australia, health priorities and policies 1998 to 2008. Canberra: Australian Institute of Health and Welfare and the University of Sydney, 2009.
57. Li Z, McNally L, Hilder L., et al Australia's mothers and babies 2009. Perinatal statistics series no. 25. Cat. no. PER 52. Sydney: Australian Institute of Health and Welfare National Perinatal Epidemiology and Statistics Unit, 2011.
58. Breheny N, O'Leary P, Dickinson J, et al Statewide evaluation of first trimester screening for Down syndrome and other fetal anomalies in Western Australia. Genomics Occasional Paper 5. Prenatal Diagnosis Committee Department of Health Western Australia, 2005.
59. Marteau TM, Bekker H. The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). Br J Clin Psychol 1992;31(Pt 3):301-6.
60. O'Connor A. User Manual-Decisional Conflict Scale (16 item statement format). Ottawa: Ottawa Hospital Research Institute.
61. Crawford JR, Henry JD The Depression Anxiety Stress Scales (DASS): normative data and latent structure in a large non-clinical sample. Br J Clin Psychol 2003;42(Pt 2):111-31. (Pubitemid 36781039)
62. Lovibond SH, Lovibond PF Manual for the depression anxiety stress scales 2nd edn. Sydney: Psychology Foundation, 1995.
63. Janz NK, Becker MH The health bBelief model: a decade later. Health Educ Q 1984;11:1-47.
64. O'Connor A. User manual-decision regret scale. Ottawa: Ottawa Hospital Research Institute.
65. Tassone F, Pan R, Amiri K., et al A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations. J Mol Diagn 2008;10:43-9. (Pubitemid 351184834)
66. Khaniani MS, Kalitsis P, Burgess T., et al An improved diagnostic PCR assay for identification of cryptic heterozygosity for CGG triplet repeat alleles in the fragile X gene (FMR1). Mol Cytogenet 2008;1:5.
67. Chen L, Hadd A, Sah S., et al An information-rich CGG repeat primed PCR that detects the full range of fragile X expanded alleles and minimizes the need for southern blot analysis. J Mol Diagn 2010;12:589-600.
68. McConkie-Rosell A., Finucane B, Cronister A., et al Genetic counseling for fragile X syndrome: updated recommendations of the National Society of Genetic Counselors. J Genet Couns 2005;14:249-70. (Pubitemid 41095420)
69. Localio AR, Margolis DJ, Berlin JA Relative risks and confidence intervals were easily computed indirectly from multivariable logistic regression. J Clin Epidemiol 2007;60:874-82. (Pubitemid 47208538)
70. Hsieh HF, Shannon SE Three approaches to qualitative content analysis. Qual Health Res 2005;15:1277-88. (Pubitemid 41645161)
71. Charmaz K. Constructing grounded theory: a practical guide through qualitative analysis. Los Angeles: Sage, 2006.